Study of CAR T cells for light chain amyloidosis
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a type of immunotherapy called CAR T cells that target a protein called BCMA on abnormal cells. It is for people whose light chain amyloidosis has come back or not responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of light chain amyloidosis that has returned or not responded to at least two prior treatments.
- You must have a certain level of abnormal light chains in your blood (dFLC > 50 mg/L).
- Your heart, liver, kidneys, and blood counts must be within acceptable ranges.
- You cannot have other active cancers, serious infections, or severe heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
This early-stage trial tests a new cell therapy using your own immune cells (genetically modified to target amyloid-producing cells) to treat light chain amyloidosis that hasn't responded to standard treatments. The goal is to help patients whose disease has come back or stopped responding to previous therapies.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
This trial tests a new CAR-T cell treatment that targets both CD19 and BCMA proteins on cancer cells. It may help people with multiple myeloma, plasma cell leukemia, or related cancers that have not responded to at least three prior treatments.
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
Hear when a new Light Chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.